In today’s recent session, 2.31 million shares of the Moderna Inc (NASDAQ:MRNA) have been traded, and its beta is 1.84. Most recently the company’s share price was $32.38, and it changed around -$0.22 or -0.67% from the last close, which brings the market valuation of the company to $12.46B. MRNA at last check was trading at a discount to its 52-week high of $170.47, offering almost -426.47% off that amount. The share price’s 52-week low was $31.94, which indicates that the recent value has risen by an impressive 1.36% since then. We note from Moderna Inc’s average daily trading volume that its 10-day average is 12.32 million shares, with the 3-month average coming to 10.67 million.
Moderna Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.79. If we narrow it down even further, the data shows that 1 out of 26 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 15 recommended MRNA as a Hold, whereas 5 deemed it a Buy, and 3 rated it as Underweight. Moderna Inc is expected to report earnings per share of -2.72 for the current quarter.
Moderna Inc (NASDAQ:MRNA) trade information
Instantly MRNA has been showing red trend so far today with a performance of -0.67% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 37.92 on recent trading dayincreased the stock’s daily price by 14.61%. The company’s shares are currently down -22.13% year-to-date, but still down -11.41% over the last five days. On the other hand, Moderna Inc (NASDAQ:MRNA) is -24.99% down in the 30-day period. We can see from the shorts that 43.01 million shares have been sold at a short interest cover period of 4.04 day(s).
The consensus price target as assigned by Wall Street analysts is $75, which translates to bulls needing to increase their stock price by 56.83% from its current value. Analyst projections state that MRNA is forecast to be at a low of $55 and a high of $238.
Moderna Inc (MRNA) estimates and forecasts
The year-over-year growth rate is expected to be -52.92%, down from the previous year.
Consensus estimates provided by 16 financial analysts predict the company will bring in an average of 951.09M in revenue for the current quarter. 7 analysts expect Moderna Inc to make 190.36M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.81B and 167M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -66.17%. Forecasts for the next quarter put sales growth at 13.99%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -20.02%. Moderna Inc earnings are expected to increase by 26.77% in 2025, but the outlook is positive 16.93% per year for the next five years.
MRNA Dividends
Moderna Inc’s next quarterly earnings report is expected to be released in March.
Moderna Inc (NASDAQ:MRNA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.59% of Moderna Inc shares, and 68.29% of them are in the hands of institutional investors. The stock currently has a share float of 75.54%. Moderna Inc stock is held by 1137.0 institutions, with BAILLIE GIFFORD & CO being the largest institutional investor. By 2024-06-30, it held 11.3741% of the shares, which is about 43.45 million shares worth $5.16 billion.
VANGUARD GROUP INC, with 10.3568% or 39.56 million shares worth $4.7 billion as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund were the top two Mutual Funds as of Sep 30, 2024. The former held 11.0 shares worth $353.9 million, making up 2.86% of all outstanding shares. On the other hand, Vanguard 500 Index Fund held roughly 8.86 shares worth around $285.07 million, which represents about 2.30% of the total shares outstanding.
